Gline Matthew

CEO, DirectorRoivant Sciences Ltd. (ROIV) · full profile →Form 4 · filed Dec 17, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$37.7M
Net Open-Market Flow
-$37.7M
Transactions
12
9 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 15, 2025Sell(S)944K$21.68$20.5M18.6M
Dec 15, 2025Other(J)4K$21.68$81K17.3M
Dec 15, 2025Option exercise(M)2.3M$12.68$28.8M19.6M
Dec 15, 2025Option exercise(M)234K$4.06$950K17.5M
Dec 15, 2025Sell(S)230K$21.68$5.0M17.3M
Dec 15, 2025Option exercise(M)1.4M$12.68$17.3M18.7M
Dec 15, 2025Sell(S)566K$21.68$12.3M18.1M
Dec 15, 2025Other(J)798K$21.68$17.3M17.3M
Dec 15, 2025Other(J)1.3M$21.68$28.8M17.3M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 15, 2025Option exercise(M)2.3M$00
Dec 15, 2025Option exercise(M)234K$00
Dec 15, 2025Option exercise(M)1.4M$00

Transaction Codes

S
Open-market sale
J
Other acquisition / disposition
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001140361-25-045906) within minutes of acceptance. Every field above traces to the original document. Verify it directly: